Background {#Sec1}
==========

Some parasites have been implicated as risk factors for certain cancers, including *Schistosoma haematobium* for bladder cancer and *Clonorchis sinensis* for liver cancer and bile duct cancer \[[@CR1]\]. However, other parasites, such as *Trypanosoma cruzi, Toxoplasma gondii, Toxocara Canis*, and *Acanthamoeba castellani,* have been suggested to improve the survival of cancer-bearing mice \[[@CR2]\]. Regarding malaria parasites specifically, there are two opposing viewpoints. In 1981, Greentree proposed that malaria infection might enhance the host's immune system and could serve as an adjuvant to conventional cancer therapy \[[@CR3]\]. In contrast, in 1990, Eze suggested that malaria infection might trigger the production of reactive oxygen species or could activate oncogenes and eventually lead to cancer \[[@CR4]\]. One previous study suggested that malaria incidence and all-cancer mortality might be positively correlated \[[@CR5]\]. The author compared malaria incidence data from 1994 with all-cancer mortality for the period 1950--1994 in United States. However the results were limited because the time spans for cancer mortality and malaria incidence did not match, and there were many potential confounders, particularly due to variations in economic development and immigration across the states. In 1994, the entire United States had fewer than 1000 imported cases of malaria, and it is known that immigrants usually target more economically advanced cities. It has been known that a positive correlation exists between malaria infection and the incidence of Burkitt's lymphoma (BL) in African children \[[@CR6], [@CR7]\]. However, no study has systematically examined the correlation between endemic malaria and the incidences or mortality rates of other cancers.

Some reports using animal models have suggested a link between malaria infection and the incidences or mortality rates of certain cancers. Trager et al. reported that the plasma of malaria-infected chickens could inhibit a chicken Rous I tumor \[[@CR8]\]. Contradictory results have been reported for liver cancer and malaria in rat models \[[@CR9], [@CR10]\]. We recently demonstrated that malaria infection inhibited tumor growth and metastasis and prolonged the survival of tumor-bearing mice in a murine Lewis lung cancer (LLC) model \[[@CR11]\]. *Plasmodium yoelii* 17XNL (a benign form of a murine malaria parasite) infection inhibited tumor angiogenesis in mice and induced innate and adaptive antitumor responses in LLC-bearing mice, leading to the induction of antitumor and anti-metastatic activities.

To examine whether such an association also exists in humans, we systematically analyzed malaria and all-cause cancer and 29 individual cancer statistical data in 56 countries from WHO publications and databases for the period 1955--2008.

Methods {#Sec2}
=======

Malaria data {#Sec3}
------------

Data regarding malaria cases for the following time periods were collected from the following sources: 1955--1964, WHO Epidemiological and Vital Statistics Report (1966); 1962--1981, WHO World Health Statistics Annual (1983); 1982--1997, WHO Weekly Epidemiological Record (1999); and 1990--2008, WHO 2009 annual report. In the event of a short overlap between two reports, data from the later report were used. We compiled worldwide malaria data from 218 countries for the period 1955--2008. Worldwide population data for 228 countries during the period 1955--2008 were obtained from the International Database of the U.S. Census Bureau (<http://www.census.gov>). The malaria incidence was calculated by dividing the number of reported malaria cases by the country's overall population; malaria incidence data were produced for 170 countries in this way.

Cancer data {#Sec4}
-----------

Age-standardized mortality data on all-cause cancer and 29 individual types of cancer (1955--2008) from 194 countries were obtained from the WHO cancer mortality database (<http://www-dep.iarc.fr/WHOdb/WHOdb.htm>); the database provides statistics separately for each gender. As shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1, merging the cancer mortality data (1955--2008) with the malaria incidence data provided combined data for 56 countries. Income information for these 56 countries was obtained from the World Bank database (<http://data.worldbank.org/country>). Data on life expectancies at birth (both sexes combined) and location data from the 56 countries were obtained from a publication of the Population Division of the United Nations Department of Economic and Social Affairs (World Population Prospects: The 2012 Revision; <http://esa.un.org/wpp/>).

Epidemiological data analysis {#Sec5}
-----------------------------

Using longitudinal malaria incidence and cancer mortality data from 56 countries, we examined trends in malaria incidence and all-cause cancer mortality for each country via linear regression. We then applied a generalized additive mixed model (GAMM) to examine the association between malaria incidence and cancer mortality. GAMM has the ability to set a random intercept to fit a wide range of cancer mortality rates among countries, to examine the nonlinear relationship between malaria incidence and cancer mortality, and to adjust for a nonlinear year effect and potential confounders such as country's income levels, life expectancies and geographical locations.

We first examined the distributions of the malaria incidence and cancer mortality rates and then log-transformed the malaria incidence and cancer mortality rates before inputting the rates into the models. All the analyses were performed using Empower software ([www.empowerstats.com](http://www.empowerstats.com), X&Y solutions, Inc., Boston, MA) and R software (<http://www.R-project.org>).

Results {#Sec6}
=======

Of the 56 countries examined, the data integrity was different from country to country. The 56 countries provide average 23-year data, while Venezuela has 50-year data, but both Barbados and Kuwait have only 6-year data. Twenty nine countries provide the data of 1955--1981, 9 countries provide the data of 1982--2008, 18 countries have the data of 1955--2008. Thirty four countries locate in Asia/Africa/Latin America, among them 3 (Egypt, Mauritius and South Africa) in Africa, and 22 in Eruope/North America/Oceania. Twenty five countries were classified as high-income (high), and 31 were classified as low- and middle-income (low).

We first drew a smooth curve fitting the malaria incidence and the all-cause cancer mortality. The year 1981 was defined as a turning point; in this year, the malaria incidence increased, and the all-cause cancer mortality decreased significantly. We thus divided the study period into two periods: 1955--1981 and 1982--2008 in the following analysis. In addition, 24 countries showed a significant (*P* \<0.05) increasing trend (up) in malaria incidence, 8 countries showed a significant decreasing trend (down) in malaria incidence, and 24 countries showed a non-significant change over the years (no change). We summarized the malaria incidence and all-cause cancer mortality data for the 56 countries from 1955--2008 in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of malaria incidence and all-cause cancer mortality in 56 countriesCountryPeriodNMalaria incidenceAll cancersMaleFemaleMedian (Min-Max)Yr. ratio^a^Median (Min-Max)Yr. ratioMedian (Min-Max)Yr. ratioArgentina1966-2008431.80 (0.26-7.08)0.97152.62 (132.01-199.59)0.9995.59 (86.39-124.56)0.99Armenia1982-2008224.84 (0--37.91)1.24\*135.54 (115.84-150.75)1.0180.115 (69.29-90.5)1.01Australia1955-1981271.29 (0.39-4.30)1.07\*151.21 (128.66-164.78)1.0198.43 (95.23-101.73)1.00Austria1955-1981260.08 (0.01-1.24)1.15\*189.84 (181.83-199.04)1.00128.935 (113.45-138.06)0.99Azerbaijan1982-2007224.7 (0.28-161.40)1.1116.3 (77.16-149.99)0.9864.825 (47.8-79.77)0.99Barbados1976-198160.60 (0.40-2.82)0.75125.56 (118.13-141.62)1.01102.3 (90.87-107)0.98Belgium1955-1981210.05 (0.01-0.60)1.14\*195.63 (153.64-216.35)1.01117.84 (111.95-126.6)1.00Belize1971-1999211505.52 (26.4-4696.7)1.15\*58.13 (26.39-147.75)1.0255.69 (36.51-131.28)1.01Brazil1979-200828281.77 (124.94-404.38)1.0193.62 (85.36-103.3)1.0167.41 (63.96-72.99001)1.00Bulgaria1964-1981170.15 (0.05-4.74)1.28\*128.08 (117.99-142.31)0.9981.82 (77.03-89.66)0.99Canada1955-1981240.03 (0--2.57)1.22\*150.21 (134.13-162.86)1.01109.23 (104.19-115.47)1.00Colombia1955-200839301.58 (81.42-588.20)1.0196.9 (61.78-103.77)1.0185.15 (71.38-97.2)1.00Costa Rica1961-20084734.45 (4.54-279.67)1103.62 (87.74-124.21)1.0088.79 (65.97-100.72)1.00Cuba1970-1981121.29 (0.01-5.90)1.61\*133.21 (123.91-139.03)0.9992.24 (85.03-95.82)0.99Denmark1955-1981260.33 (0.11-2.15)1.09\*165.54 (151.26-181.88)1.00135.72 (125.75-145.28)1.00Dominican Republic1970-20053114.05 (3.15-83.90)142.58 (34.04-61.54)1.0139.33 (34.97-51.95)1.00Ecuador1977-200829362.59 (34.07-890.54)0.9871.42 (55.09-78.69)1.0071.52 (59.06-78.98)1.00Egypt1955-2008170.10 (0.01-474.70)0.85\*41.35 (22.02-50.13)1.0126.23 (13.32-33.14)1.02El Salvador1958-200834147.79 (0.55-1924.15)0.88\*39.99 (21.8-60.4)1.0254.05 (34.52-68.83)1.01Finland1965-1981150.09 (0.02-0.47)1.16\*184.27 (177.38-195.1)0.9998.47 (94.04-106.99)0.99France1955-1981240.04 (0--1.03)1.14\*185.97 (149.46-207.7)1.01100.655 (94.08-106.6)0.99Georgia1990-2007160.43 (0.02-9.25)1.43\*79.99 (62.51-102.93)1.0052.14 (41.88-66.36)1.00Greece1961-1981210.55 (0.30-1.77)0.96\*125.41 (116.45-145.84)1.0175.95 (71.89-82.94)1.01Guatemala1963-200825445.36 (69.81-1004.5)1.0167.03 (38.95-78.97)1.0275.595 (50.07-84.01)1.01Hungary1955-1981270.06 (0.01-0.46)0.98170.12 (130.85-214.48)1.02121.71 (114.18-129.34)1.00Ireland1955-1981170.07 (0.03-0.98)1.13\*158.37 (128.77-169.4)1.01121.11 (107.84-130.69)1.01Israel1975-198170.48 (0.27-1.16)1.24\*131.36 (118.82-137.7)0.99113.88 (107.84-116.67)0.99Italy1955-1981270.07 (0.01-0.43)1.11\*160.04 (123.09-187.98)1.02100.25 (96.73-103.36)1.00Japan1955-1981270.03 (0.01-0.07)1.03143.55 (125.39-149.85)1.0094.36 (84.6-99.17)0.99Kuwait1975-1981611.93 (7.15-16.04)0.88\*94.08 (89.14-142.41)0.9573.56 (56.31-85.91)1.02Kyrgyzstan1990-2008190.27 (0--54.73)1.34103.2 (95.9-139.63)0.9866.97 (62.79-79.04)1.00Mauritius1961-1989295.57 (1.26-67.34)1.0896.93 (72.36-134.73)1.0168.86 (55.38-84.72)0.99Mexico1969-20083222.03 (2.14-174.16)0.9\*73.52 (51.76-76.71)1.0168.87 (64.13-73.67)1.00New Zealand1955-1981260.48 (0.09-2.23)1.04157.77 (134.46-175.78)1.01114.795 (108.98-124.02)1.00Nicaragua1973-200825524.44 (13.95-1679.01)0.9449.55 (15.79-59.14)1.0452.13 (21.9-61.56)1.03Norway1955-1981210.08 (0.03-1.39)1.15\*134.65 (124.81-145.52)1.01101.08 (97.48-110.9)1.00Panama1955-20084753.18 (5.81-670.11)0.96\*73.97 (57.86-91.1)1.0166 (55.64-81.41)1.00Paraguay1988-20081521.94 (6.34-187.26)0.9472.11 (66.2-74.86)1.0063.07 (58.71-65.54)1.00Peru1966-200730179.07 (16.11-984.90)1.08\*63.9 (40.08-74.8)1.0065.13 (38.9-77.01)1.00Philippines1988-20081554.54 (24.62-249.58)0.91\*92.9 (78.82-100.9)1.0165.715 (57.07-71.5)1.01Poland1959-1981220.04 (0.01-0.10)1.04\*153.43 (103.15-181.65)1.02102.625 (81.88-106.09)1.01Portugal1955-1981271.38 (0.04-10.35)1.05121.39 (89.41-133.25)1.0184.4 (75.34-90.29)1.00Romania1963-1981130.08 (0.02-0.10)1.03127.47 (124.17-131.21)1.0086.39 (83.02-98.06)0.99Singapore1963-19811911.53 (7.05-22.80)0.98171.88 (157.07-207.55)1.01100.32 (91.53-116.34)1.01South Africa1988-20081730.16 (13.08-143.40)0.97136.65 (121.25-145.78)0.9984.31 (70.13-87.88)1.01Spain1955-1981270.09 (0.02-8.57)0.94\*134.17 (105.68-151.66)1.0186.23 (79.24001-91.09)1.00Suriname1971-2008262058.43 (152.56-14273.09)1.12\*69.16 (34.15-95.24)1.0065.26 (26.55-95.75)0.99Sweden1955-1981270.30 (0.05-1.48)1.14\*131.41 (117.91-148.03)1.01109.24 (101.89-113.42)1.00Switzerland1955-1981220.12 (0.02-2.15)1.19\*174.17 (169.64-183.12)1.00111.08 (102.52-123.75)0.99Tajikistan1982-20052275.25 (3.32-4508.57)1.46\*71.17 (52.63-110.44)0.9752.985 (36.33-69.2)0.98Thailand1959-200627175.6 (41.84-843.59)0.9958.68 (13.05-89.11)1.0436.42 (10.44-56.02)1.04Trinidad and Tobago1955-1981820.54 (0.27-213.59)0.893.44 (83.49-116.19)1.00106.055 (88.44-123.58)0.99Turkmenistan1990-199890.29 (0.03-3.21)1.39102.3 (87.32-132.92)0.9566.835 (55.55-81.32)0.96United Kingdom1962-1981200.54 (0--3.65)1.41\*186.43 (180.55-189.06)1.00120.165 (114.59-123.92)1.00Uruguay1963-197880.04 (0.03-0.15)0.95200.58 (192.12-205.04)1.00126.605 (119.13-133.04)0.99Venezuela1955-20075066.1 (7.5-249.34)1.04\*98.74 (89.01-113.05)1.0094.185 (77.43-141.76)0.99Notes: ^a^Yr. ratio: annual change ratio calculated as 10\^β, where β is the regression coefficient of the annual log-transformed malaria incidence or cancer mortalities. \**P* \< 0.05

Spline smoothing by the GAMM showed a linear inverse relationship between malaria incidence and all-cause cancer mortality. A further analysis using the linear term of malaria incidence showed that a 10-fold increase in malaria incidence was associated with a lower log-transformed all-cause cancer mortality (−0.31 \[95% CI:-0.37,-0.25\], *P* \<0.001, for men and −0.32 \[95% CI:-0.37,-0.26\], *P* \<0.001, for women; Table [2](#Tab2){ref-type="table"}). After adjusting for year, life expectancy at birth, income level, and geographical locations, this negative relationship persisted (regression coefficients: −0.20 \[95% CI:-0.27,-0.14\], *P* \<0.001, for men and −0.20 \[95% CI:-0.25,-0.14\], *P* \<0.001, for women). A stratified analysis showed an inverse relationship between malaria incidence and all-cause cancer mortality regardless of time periods, national income levels, geographical locations, or the malaria incidence trend (Table [2](#Tab2){ref-type="table"}).Table 2Regression analysis of the relationship between all-cancer mortality and malaria incidence, 1955--2008ModelMaleFemaleBasic model−0.31 (−0.37, −0.25) \*\*\*−0.32 (−0.37, −0.26) \*\*\*Adjusted model−0.20 (−0.27, −0.14) \*\*\*−0.20 (−0.26, −0.14) \*\*\*Period 1955-1981−0.11 (−0.16, −0.05) \*\*\*−0.05 (−0.10, 0.00) \*\* 1982-2008−0.24 (−0.34, −0.15) \*\*\*−0.11 (−0.19, −0.03) \*\*Income Low−0.28 (−0.37, −0.18) \*\*\*−0.25 (−0.34, −0.16) \*\*\* High−0.11 (−0.15, −0.06) \*\*\*−0.07 (−0.11, −0.03) \*\*\*Geographical location Asia/Africa/Latin America−0.27 (−0.36, −0.18) \*\*\*−0.24 (−0.33, −0.16) \*\*\* Europe/North America/Oceania−0.16 (−0.20, −0.12) \*\*\*−0.10 (−0.13, −0.06) \*\*\*Malaria incidence trend Down−0.20 (−0.31, −0.08) \*\*\*−0.25 (−0.36, −0.13) \*\*\* No change−0.13 (−0.26, 0.00) \*−0.06 (−0.18, 0.06) Up−0.21 (−0.32, −0.10) \*\*\*−0.03 (−0.12, 0.07)Notes1. Both malaria incidence and cancer mortality data were log transformed. The results shown are 10 times the regression coefficients and 95% confidence intervals2. The basic model was adjusted for year; the adjusted model was adjusted for year, life expectancy at birth, national income level and geographical location3. \*\*\**P* \<0.001; \*\**P* \<0.01; \**P* \<0.05

We then analyzed 29 individual types of cancer, and found that the inverse relationship between malaria incidence and cancer mortality was significant for colorectum and anus (both men and women), colon (both men and women), lung (men), stomach (men) and breast (women) cancer (Table [3](#Tab3){ref-type="table"}). For other individual cancers, the correlation was not as significant as for these cancers. Detailed analyses of other cancer types are given in Additional file [2](#MOESM2){ref-type="media"}: Table S2.Table 3Regression analysis of the relationship between mortality rates associated with 5 individual types of cancer and malaria incidence, 1955--2008CancerBasic modelAdjusted modelPeriod1955-19811982-2008Colon Male−0.72 (−0.87, −0.56) \*\*\*−0.52 (−0.68, −0.36) \*\*\*−0.31 (−0.48, −0.14) \*\*\*−0.59 (−0.81, −0.38) \*\*\* Female−0.87 (−1.02, −0.72) \*\*\*−0.63 (−0.78, −0.48) \*\*\*−0.39 (−0.54, −0.24) \*\*\*−0.64 (−0.86, −0.43) \*\*\*Colon, rectum and anus Male−0.51 (−0.62, −0.41) \*\*\*−0.37 (−0.47, −0.26) \*\*\*−0.25 (−0.37, −0.13) \*\*\*−0.41 (−0.58, −0.25) \*\*\* Female−0.58 (−0.68, −0.48) \*\*\*−0.42 (−0.52, −0.32) \*\*\*−0.34 (−0.46, −0.22) \*\*\*−0.45 (−0.60, −0.29) \*\*\*Lung Male−0.36 (−0.46, −0.25) \*\*\*−0.20 (−0.32, −0.09) \*\*\*−0.24 (−0.35, −0.12) \*\*\*−0.54 (−0.71, −0.37) \*\*\*Breast Female−0.46 (−0.56, −0.37) \*\*\*−0.30 (−0.40, −0.20) \*\*\*−0.20 (−0.29, −0.10) \*\*\*−0.32 (−0.45, −0.19) \*\*\*Stomach Male−0.66 (−0.76, −0.55) \*\*\*−0.39 (−0.50, −0.28) \*\*\*−0.31 (−0.40, −0.21) \*\*\*−0.23 (−0.37, −0.08) \*\*\*Notes1. Both malaria incidence and cancer mortality data were log transformed. The results are 10 times the regression coefficients and the 95% confidence intervals2. The basic model was adjusted for year; the adjusted model was adjusted for year, life expectancy at birth, national income level and geographical location3. \*\*\**P* \<0.001

The epidemiological analysis suggested that an inverse relationship exists between malaria incidence and mortality due to colorectum and anus, colon, lung, breast and stomach cancer; however, no significant correlations were found between malaria incidence and other cancers.

Discussion {#Sec7}
==========

In the present study, we utilized WHO cancer and malaria data to conduct longitudinal (1955--2008) analyses to assess the relationship between these diseases. Our analyses indicate that endemic or epidemic malaria may decrease mortality for some solid cancers, including colon cancer both in men and women, lung and stomach cancer in men, and breast cancer in women. Country-specific cancer incidence and mortality are associated with many factors, such as ethnicity, habits, customs, the level of economic development, the level of health care, and the level of cancer diagnosis and treatment. The geographical distribution of the countries is also a potential confounding factor. Malaria is widely transmitted in Africa, Asia, and Latin America but has a low incidence in industrialized countries. Another potential confounding factor is the effect of time. To reduce the effects of these confounding factors, a GAMM was used to analyze the longitudinal data. A random intercept effect for each country in the GAMM regression analysis was used to accommodate the variations in cancer mortality across different countries. After adjusting for year, life expectancy at birth, national income level, and geographical locations, the inverse relationship between malaria incidence and all-cause cancer mortality persisted. Recent studies have demonstrated that some antimalarial drugs, such as artemisinin and chloroquine, have antitumor activities \[[@CR12], [@CR13]\]; thus, malaria treatment in endemic areas may affect cancer mortality, as well. However, although artemisinin was only used in clinics after the 1990s \[[@CR14], [@CR15]\], our analysis indicated that the negative relationship between malaria incidence and all-cause cancer mortality existed before the 1990s, during the period 1955--1981. Thus, the clinical use of artemisinin should not be a major confounder. Chloroquine may have been widely used throughout the entire period 1955--2008, but it was used only for short-term (3-day) treatment of malaria; thus, it is unlikely to have significantly affected cancer mortality. Furthermore, our murine Lewis lung cancer (LLC) model studies have demonstrated that 3-day treatment with a clinically relevant dose of chloroquine does not improve the survival of tumor-bearing mice (data not shown). Therefore, it is less likely that the observed inverse relationship between malaria incidence and cancer mortality was caused by the confounding factors discussed above.

Increased levels of economic development and increased life span typically decrease malaria incidence and increase cancer mortality. Thus, in countries with low levels of malaria and controlled endemic malaria, an inverse relationship between malaria incidence and cancer mortality would be observed merely through a simple analysis. To address this issue, we included a year variable spline smoothing term in the model to control for this time effect. We also conducted simulation analyses to estimate class I errors and the statistical power using data from 8 countries with decreasing malaria incidence. The estimated probability of this finding being due to chance was \<0.035, and the power to detect our observed effect (−0.03) was 0.752. We also stratified the countries by trends in malaria incidence (up, down or no change). Negative correlations between malaria incidence and cancer mortality were observed in each stratum. Another potential time effect was the changing population structure over time because aging that relates to cancer mortality may also relate to malaria incidence. To address this issue, we stratified the years into two segments, 1955--1981 and 1982--2008, to narrow the aging effect. Negative correlations between malaria incidence and cancer mortality were still observed during each time period.

There are three limitations to the present study. First, cancer mortality and malaria incidence data were obtained from WHO publications and databases. Different countries may use different reporting criteria for the malaria incidence data. In addition, we were unable to obtain age-standardized malaria incidence data from existing databases. For cancer mortality, although the data were age-standardized for the countries studied, medical care and cancer reporting systems varied across countries and may have changed over time; these factors may affect the comparability of cancer mortality data between countries and years. Although our analysis using the GAMM approach maximally accommodated the limitations of existing data by primarily examining trends over time within each country instead of across countries, such limitations could not be completely eliminated by our data analysis. Second, we do not have other countries' data, especially the data from malaria high endemic countries in Africa. Therefore the impact of endemic malaria on cancer mortality in our analysis may mainly reflect *vivax* malaria that prevails outside Africa, not *falcipuram* malaria that prevails in Africa, even though all four species of human malaria parasite (*Plasmodium vivax, falcipuram, ovale and malariae*) contain pathogen-associated molecular patterns (PAMPs \[[@CR16]\]) that can trigger the antitumor immune response (see below). Third, the positive relationship between the incidence of Burkitt's lymphoma in African children and *falciparum* malaria has been well established, because this malaria causes a prolonged expansion of B cell in the germinal centers and therefore provides more time for DNA damage and MYC oncogene translocation that ultimately leads to Burkitts lymphoma \[[@CR17]\], but we were unable to obtain mortality or incidence data for this tumor from WHO publications or databases. Thus, our analysis model lacks information that could be used to establish a positive relationship between malaria incidence and cancer mortality; such information would be important for validating our model further.

Malaria infection may serve to enhance immune surveillance mechanisms against some types of solid cancers. During the course of malaria, *Plasmodium* PAMPs \[[@CR16]\] as danger signals are detected by the host immune cells' sensors called pattern recognition receptors (PRRs) which include the toll-like receptors (TLRs) \[[@CR18]\] at the membrane of endosomes or on the cell surface, RIG-I-like receptors (RLRs) \[[@CR19]\] and NOD-like receptors (NLRs) \[[@CR20]\] localized in cytoplasm. The *Plasmodium* PAMPs include the known glycosylphosphatidylinositol anchors (GPI anchors) \[[@CR21]\], haemozoin \[[@CR22]\] and immunostimulatory nucleic acid motifs \[[@CR23]\] and other unknown molecules \[[@CR24]\]. The PRRs activated by *Plasmodium* PAMPs trigger distinct transcriptional programs and stimulate multiple downstream pathways to induce systemic immune responses \[[@CR25]\], including release of pro-inflammatory and Th1-type cytokines such as TNF-α, IL-1β, IL-2, IL-6, IL-12, type I and type II IFNs \[[@CR25], [@CR26]\], activation of NK cells, NKT cells, γ/δ T cells, macrophages and dendritic cells (DCs), afterwards activation of CD4+ and CD8+ T cells \[[@CR26], [@CR27]\] that counteract the tumor immune-suppressive microenvironment that contains TGF-β, IL-10, regulatory T cells (Tregs) and myeloid-derived suppressive cells (MDSCs) \[[@CR28], [@CR29]\], then turn the immune-suppressive milieu to immune-supportive milieu, finally may transform the tumor into an effective tumor vaccine \[[@CR30], [@CR31]\]. On the other hand, malaria damage-associate molecular patterns (DAMPs), such as the known intrinsic uric acid, microvesicles and haem \[[@CR31]--[@CR33]\] also induce similar immune activity. Indeed, our previous study demonstrated that blood-stage malaria exhibits anti-tumor effects by inducing a potent anti-tumor innate immune response, including the secretion of IFN-γ and TNF-α and the activation of NK cells. Our murine lung cancer model studies also demonstrated that malaria infection induced adaptive anti-tumor immunity by increasing tumor-specific T-cell proliferation and the cytolytic activity of CD8^+^ T cells and increased the infiltration of these cells into tumor tissues. In these studies, we found that in approximately 10% of lung cancer (LLC)-bearing mice infected with malaria parasite, the tumor regressed and did not regrow when the mice were re-inoculated with the same cancer cells, most likely because of the long-term memory of specific antitumor cellular immunity \[[@CR11]\]. Study by Deng XF and colleagues demonstrated that attenuated liver-stage *Plasmodium* inoculation induced antitumor innate immune response, including secretion of TNF-α, IL-6/12 and IFN-γ and antitumor adaptive immunity with increasing cytolytic activity of CD8+ T cells \[[@CR34]\]. Our unpublished data suggest that blood-stage *Plasmodium* infection significantly decreases the numbers of MDSCs in breast cancer (4 T1)-bearing mice or Tregs in lung cancer (LLC)-bearing mice. In addition, our previous study indicated that malaria infection significantly inhibited tumor angiogenesis in mice \[[@CR11]\]. A review by Hobohm \[[@CR35]\] suggested that the fever induced by malaria infection may cause an increase in tumor cell death. Based on our previous study and our unpublished data, parasitemia is required to effectively inhibit tumor growth. However, in mice, *Plasmodium* infection causes only a short-term infection without fever. Repeated *Plasmodium* infection is difficult to observe in murine models \[[@CR36]\]. In humans lacking effective antimalarial treatment, *Plasmodium* infection can cause long-term parasitemia that is accompanied by a high fever in the acute phase, and this syndrome can recur many times throughout the life span \[[@CR37]\]. Therefore, a naturally acquired *Plasmodium* infection by mosquito bite would produce liver-stage and blood-stage malaria that sequentially stimulate the immune systems to turn the tumor into the effective tumor vaccine, in combination with fever during the acute phase and the inhibition of tumor angiogenesis. In medical literature, febrile infection was linked to spontaneous regression of tumor \[[@CR38]\], and malaria is a typical febrile infection. Other pathogen infections may have similar impact on cancer mortality or morbidity \[[@CR39], [@CR40]\], due to a similar mechanism of PAMPs-triggered antitumor immunity \[[@CR41]\], but malaria parasite may be more significant than other pathogens, because malaria contains two stages (liver and blood) of infection, manifests typical high fever paroxysms during acute phase and may last longer period if not treated with effective antimalarial drugs. In addition, malaria is a well-documentary infectious disease in WHO databases and publications partially due to easily to be diagnosed by fever paroxysm and a simple blood smear test. Other pathogen infections lack well-documentary data in WHO databases or publications for analysis. In summary, some or all of these above mentioned factors and mechanisms may explain why endemic malaria might reduce cancer mortality at the population level.

Conclusion {#Sec8}
==========

We report an inverse association between malaria incidence and the mortality rates of all-cause and several types of solid cancers. However, because this study is a descriptive retrospective analysis, we are unable to draw a causal relationship between malaria and the mortality rates of some cancers. More well-defined prospective epidemiological studies are required to confirm this relationship. We recommend that public health officials in the WHO and in individual countries coordinate malaria control programs and cancer epidemiological studies in the future. In addition, more comprehensive mechanistic studies should be conducted.
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